Pratik S. Multani - 15 Dec 2025 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
Chief Medical Officer
Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
15 Dec 2025
Net transactions value
-$97,129
Form type
4
Filing time
17 Dec 2025, 19:21:01 UTC
Previous filing
26 Jun 2025
Next filing
05 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Multani Pratik S Chief Medical Officer C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO /s/ Christian Kuhlen, attorney-in-fact 17 Dec 2025 0001586894

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORIC Common Stock Options Exercise $0 +29,333 +59% $0.000000 78,869 15 Dec 2025 Direct F1, F2
transaction ORIC Common Stock Sale $97,129 -10,720 -14% $9.06 68,149 16 Dec 2025 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORIC Restricted Stock Unit Options Exercise $0 -8,000 -100% $0.000000 0 15 Dec 2025 Common Stock 8,000 Direct F1, F5
transaction ORIC Restricted Stock Unit Options Exercise $0 -10,000 -50% $0.000000 10,000 15 Dec 2025 Common Stock 10,000 Direct F1, F6
transaction ORIC Restricted Stock Unit Options Exercise $0 -11,333 -33% $0.000000 22,667 15 Dec 2025 Common Stock 11,333 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
F2 Includes an aggregate of 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
F3 Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
F4 Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0449 to $9.1451 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
F6 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.
F7 1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.